Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04774536|
Recruitment Status : Not yet recruiting
First Posted : March 1, 2021
Last Update Posted : January 9, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease||Drug: CRISPR_SCD001||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease|
|Estimated Study Start Date :||June 1, 2023|
|Estimated Primary Completion Date :||June 1, 2025|
|Estimated Study Completion Date :||June 1, 2028|
Experimental: CRISPR_SCD001 Drug Product
CRISPR_SCD001 Drug Product (autologous CD34+ cell-enriched population that contains cells modified by the CRISPR-Cas9 ribonucleoprotein) dose will be ≥3.0×106 CD34+ cells/kg recipient weight for each subject and the upper limit cell dose is 20 ×106 CD34+ cells/kg.
CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
- Incidence of adverse events and grade 3 or higher serious adverse events, using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: 24 months post-transplant ]The adverse event rate will be summarized using descriptive statistics, together with 95% confidence intervals where appropriate. No formal statistical hypothesis testing will be performed. Adverse events defined: failure of engraftment, malignant clonal expansion related to genomic editing or death.
- Change in the annualized vaso-occlusive pain event (VOE) rates. [ Time Frame: 24 months pre-transplant to 24 months post-transplant ]Change in the annualized vast-occlusive pain event (VOE) rates comparing the 24 months before with 24 months after the infusion of drug product.
- Graft rejection defined as having an absolute neutrophil count (ANC) < 500 at 42 days post-infusion [ Time Frame: 42 days post-transplant ]A delay in platelet and/or neutrophil engraftment will be captured.
- Time to neutrophil recovery defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count (ANC) of ≥500/µL after transplant. [ Time Frame: 24 months post-transplant ]Neutrophil recovery as part of the overall hematological recovery.
- Time to platelet recovery is defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count > 50,000/µL AND did not receive a platelet transfusion in the previous 7 days. [ Time Frame: baseline, through 24 months post-transplant ]Platelet recovery as part of the overall hematological recovery.
- Rate of improvement in Hemoglobin S (HbS) fraction as measured by hemoglobin electrophoresis, as percent of total. [ Time Frame: baseline, through 24 months post-transplant ]Hemolysis markers.
- Rate of normalization in hemoglobin (hgb) level as measured by clinical hematology (laboratory) test. [ Time Frame: baseline, through 24 months post-transplant ]Hemolysis markers.
- Rate of normalization of lactate dehydrogenase (LDH), reticulocyte count, and haptoglobin, as measured by clinical hematology and serum chemistry (laboratory) tests. [ Time Frame: baseline, through 24 months post-transplant ]Hemolysis markers.
- Frequency of hepatic veno-occlusive disease (VOD) as measured by Seattle or Baltimore Criteria for VOD Diagnosis. [ Time Frame: 24 months post-transplant ]Hematologic and non-hematologic toxicities of autologous transplantation with CRISPR-Cas9 sickle-corrected HSPCs.
- Frequency of hepatic idiopathic pneumonia syndrome (IPS) as measured by the Idiopathic pneumonia syndrome (IPS) criteria. [ Time Frame: 24 months post-transplant ]Hematologic and non-hematologic toxicities of autologous transplantation with CRISPR-Cas9 sickle-corrected HSPCs.
- Frequency of central nervous system (CNS) toxicity (reversible posterior leukoencephalopathy syndrome [RPLS] or posterior reversible encephalopathy syndrome [PRES], hemorrhage, and seizures). [ Time Frame: 24 months post-transplant ]Hematologic and non-hematologic toxicities of autologous transplantation with CRISPR-Cas9 sickle-corrected HSPCs.
- Frequency of cytomegalovirus (CMV) infection, invasive fungal infection, and any other serious viral or bacterial infection [ Time Frame: 24 months post-transplant ]Hematologic and non-hematologic toxicities of autologous transplantation with CRISPR-Cas9 sickle-corrected HSPCs.
- Frequency of sickle gene-editing (correction and insertion/deletion) and off-target site-1 editing in marrow and peripheral blood mononuclear cells. [ Time Frame: 3 months, 1 and 2 years post-transplant ]Stability of gene-editing in hematopoietic cells by genotyping studies.
- Rate of sickle-related events other than severe VOE and end organ function. [ Time Frame: 24 months post-infusion ]Rate of sickle-related complications after infusion
- Patient-reported quality of life (pain and fatigue domains) as measured by the use of Patient Reported Outcome Measurement Information System (PROMIS) modules. [ Time Frame: baseline, and 1 and 2 years post-transplant ]
Change in quality of life score at baseline (prior to the initiation of hydroxyurea), 1 year and 2 years post-stem cell infusion accessed using Patient Reported Outcome Measurement Information System (PROMIS) modules. The PROMIS modules rate the following areas:
- Physical Function and Sleep Quality on a scale of 1 (not good) to 5 (good).
- Anxiety, Depression, Fatigue, Pain Interference and the Ability to Participate in Social Roles and Activities on a scale of 1 (never) to 5 (always).
- Pain Intensity on a scale from 0 (no pain) to 10 (worst pain imaginable).
- Change from baseline in cardiac-pulmonary function via pulmonary function tests [ Time Frame: Through 1 and 2 years post-transplant ]
- Change from baseline in cardiac-pulmonary function via echocardiogram (tricuspid regurgitant jet velocity [TRJV], LVEF). [ Time Frame: Through 1 and 2 years post-transplant ]
- Change from baseline in meters walked during 6-minute walk test (6MWD) [ Time Frame: Through 1 and 2 years post-transplant ]
- Event-free survival defined as survival without clinical and hematological evidence of the underlying Sickle Cell Disease (SCD) [ Time Frame: 1 and 2 years post-transplant ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Years to 35 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Male or female 12.00 - 34.99 years of age (at time of consent) who have one or more of the following:
- History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea);
- History of at least 4 severe vaso-occlusive pain events in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea); painful episodes related to or any sickle-related acute event are acceptable; a severe painful vaso-occlusive event is defined as receiving analgesic treatment (opioid or other analgesic) for longer than 24 -hours in a hospital or emergency room (ER) observation unit visit or at least 2 visits in a day unit or ER over 72 hours with both visits requiring intravenous analgesics.
Participants must have adequate physical function as measured by all of the following:
- Karnofsky performance score ≥60.
- Cardiac function: Left ventricular ejection fraction (LVEF) >40%; or LV shortening fraction > 26% by cardiac echocardiogram or by (multiple-gated acquisition) MUGA scan.
- Pulmonary function: Pulse oximetry with a baseline O2 saturation of ≥85% and diffusion capacity of lung for carbon monoxide(DLCO) > 40% (corrected for hemoglobin).
- Renal function: Serum creatinine ≤ 1.5 x upper limit of normal for age and estimated or measured creatinine clearance ≥ 70 mL/min/1.73 m2.
- Hepatic function:
i. Serum conjugated (direct) bilirubin < 2x upper limit of normal for age as per local laboratory. Participants with hyperbilirubinemia as the result of hyperhemolysis, or a severe drop in hemoglobin post blood transfusion, are not excluded.
ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AS < 5 times upper limit of normal as per local laboratory.
f. Liver MRI using a validated methodology per institutional preference (T2* or R2* or by ferriscan [R2 MRI]) for estimation of hepatic iron content is required for participants who are currently receiving ≥8 packed red blood cell transfusions per year for ≥1 year or have received ≥20 packed red blood cell transfusions (lifetime cumulative). Participants who have hepatic iron content ≥ 8 mg Fe/g liver dry weight by liver MRI must have a Gastroenterology/hepatology consultation with liver biopsy and histological examination including documentation of the absence of cirrhosis, bridging fibrosis, and active hepatitis.
- Written informed consent or assent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- Participants with uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).
- Participants with evidence of HIV infection or seropositivity for HIV or active hepatitis B or C.
- Participants who have received a Hematopoietic Cell Transplant (HCT)
- Participants who have received a solid organ transplant.
- Participants who have participated in another clinical trial in which the participant received an investigational or off-label use of a drug or device within 3 months prior to enrollment.
- Females who are pregnant or breast feeding.
- Females of child bearing potential (to include all female participants > 10 years of age, unless postmenopausal for a minimum of 1 year before the time of consent or surgically sterilized) who do not agree to practice two (2) effective methods of contraception at the same time, or who do not agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject, from the time of signing of informed consent through 12 months post-stem cell infusion.
- Males (even if surgically sterilized) who do not agree to practice effective barrier contraception, or who do not agree to practice true abstinence from the time of signing informed consent through 12 months post-stem cell infusion.
- Participants who have had a stroke OR who are receiving red blood cell (RBC) transfusions to prevent primary stroke or silent cerebral infarction.
- Patients who have a human leukocyte antigen identical (HLA-ID) sibling donor
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Any non-homozygous sickle hemoglobin (HbSS) genotype of SCD
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04774536
|Contact: Mark Walters, MD||(510) 428-3374||Mark.Walters@ucsf.edu|
|Contact: Christina Chun, MPH||(415) 502-2558||Christina.Chun@ucsf.edu|
|United States, California|
|University of California, Los Angeles|
|Los Angeles, California, United States, 90095|
|Contact: Augustine Fernandes, PhD firstname.lastname@example.org|
|Principal Investigator: Donald B Kohn, MD|
|UCSF Benioff Children's Hospital|
|Oakland, California, United States, 94609|
|Contact: Cyrus Bascon 510-428-3885 ext 6953 Cyrus.Bascon@ucsf.edu|
|Principal Investigator: Mark Walters, MD|
|Principal Investigator:||Mark Walters, MD||UCSF Benioff Children's Hospital Oakland|
|Responsible Party:||Mark Walters, MD, Professor in Residence, University of California, San Francisco|
|Other Study ID Numbers:||
|First Posted:||March 1, 2021 Key Record Dates|
|Last Update Posted:||January 9, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn